118 related articles for article (PubMed ID: 35734511)
1. Poromas with
Yamamoto M; Kawase Y; Kishi H; Miyoshi Y; Mitsui H; Sekine S
JAAD Case Rep; 2022 Jul; 25():39-42. PubMed ID: 35734511
[No Abstract] [Full Text] [Related]
2. YAP1::MAML2 fusions in poromatosis: A report of two patients.
Mitsui Y; Ogawa K; Goto K; Fujii T; Nakamura-Nishimura Y; Mashiba K; Asada H
J Cutan Pathol; 2023 Aug; 50(8):695-701. PubMed ID: 36723803
[TBL] [Abstract][Full Text] [Related]
3. Loss of YAP1 C-terminus expression as an ancillary marker for metaplastic thymoma: a potential pitfall in detecting YAP1::MAML2 gene rearrangement.
Wang X; Liu LL; Li Q; Xia QY; Li R; Ye SB; Zhang RS; Fang R; Chen H; Wu N; Rao Q
Histopathology; 2023 Nov; 83(5):798-809. PubMed ID: 37565303
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of NUT-positive poromas and porocarcinomas identifies novel break points of YAP1::NUTM1 fusions.
Snow JT; Georgantzoglou N; Green DC; Parra O; LeBlanc RE; Yan S; Sriharan A; Momtahen S; Winnick KN; Dimonitsas E; Stavrianos S; Lakiotaki E; Korkolopoulou P; Revelos K; Guo R; Linos K
J Cutan Pathol; 2022 Oct; 49(10):850-858. PubMed ID: 35665951
[TBL] [Abstract][Full Text] [Related]
5. Eccrine Poromatosis: Case Report, Review of the Literature, and Treatment.
Mayo TT; Kole L; Elewski B
Skin Appendage Disord; 2015 Sep; 1(2):95-8. PubMed ID: 27170941
[TBL] [Abstract][Full Text] [Related]
6. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.
Sekine S; Kiyono T; Ryo E; Ogawa R; Wakai S; Ichikawa H; Suzuki K; Arai S; Tsuta K; Ishida M; Sasajima Y; Goshima N; Yamazaki N; Mori T
J Clin Invest; 2019 May; 129(9):3827-3832. PubMed ID: 31145701
[TBL] [Abstract][Full Text] [Related]
7. Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma.
Russell-Goldman E; Hornick JL; Hanna J
J Cutan Pathol; 2021 Mar; 48(3):403-410. PubMed ID: 33222286
[TBL] [Abstract][Full Text] [Related]
8. Poromatosis in pregnancy: a case of 8 eruptive poromas in the third trimester.
North JP; Lo J; Landers M
Cutis; 2012 Feb; 89(2):81-3. PubMed ID: 22474731
[TBL] [Abstract][Full Text] [Related]
9. Multiple Plantar Poromas in a Stem Cell Transplant Patient.
Marsh RL; Kaffenberger B; Pootrakul L; Chung C
Cureus; 2020 Jun; 12(6):e8773. PubMed ID: 32742823
[TBL] [Abstract][Full Text] [Related]
10. Eccrine poromatosis in a patient with acute myeloid leukemia following chemotherapy.
Garshick M; DeFilippis EM; Harp J; Gaan J
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419754
[TBL] [Abstract][Full Text] [Related]
11. Eccrine poromatosis following chemotherapy and radiation therapy.
Nguyen K; Kim G; Chiu M
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045152
[TBL] [Abstract][Full Text] [Related]
12. Poromatosis: the occurrence of multiple eccrine poromas.
Navi D; Fung M; Lynch PJ
Dermatol Online J; 2008 Jan; 14(1):3. PubMed ID: 18319020
[TBL] [Abstract][Full Text] [Related]
13. Eccrine poromatosis associated with polychemotherapy.
Fujii K; Aochi S; Takeshima C; Ohtsuka M; Hamada T; Asagoe K; Aoyama Y; Morizane S; Iwatsuki K
Acta Derm Venereol; 2012 Nov; 92(6):687-90. PubMed ID: 22294042
[TBL] [Abstract][Full Text] [Related]
14. Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases.
Kervarrec T; Westphal D; Pissaloux D; Legrand M; Tirode F; Neuhart A; Drouot F; Becker JC; Macagno N; Seris A; Jouary T; Beltzung F; Jullie ML; Harms PW; Cribier B; Mourah S; Jouenne F; Fromont G; Louveau B; Mancini M; Kazakov DV; de la Fouchardière A; Battistella M
Histopathology; 2024 May; ():. PubMed ID: 38785043
[TBL] [Abstract][Full Text] [Related]
15. A Case of Eccrine Poromatosis in a Patient with a History of Chemotherapy Due to Stomach Cancer.
Choi IH; Yu DS; Lee YB
Ann Dermatol; 2020 Oct; 32(5):422-425. PubMed ID: 33911778
[TBL] [Abstract][Full Text] [Related]
16. Eruptive poromatosis in a patient with breast cancer.
Lim TM; Weir J; Fearfield L
J Cutan Pathol; 2018 May; ():. PubMed ID: 29797732
[TBL] [Abstract][Full Text] [Related]
17. Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features.
Nakano S; Okumura Y; Murase T; Nagao T; Kusafuka K; Urano M; Yamamoto H; Kano S; Tsukahara K; Okami K; Kawakita D; Nagao T; Hanai N; Iwai H; Kawata R; Tada Y; Nibu KI; Inagaki H
Histopathology; 2022 Mar; 80(4):729-735. PubMed ID: 34657306
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma.
Morita M; Murase T; Okumura Y; Ueda K; Sakamoto Y; Masaki A; Kawakita D; Tada Y; Nibu KI; Shibuya Y; Inagaki H
Histopathology; 2020 Jun; 76(7):1013-1022. PubMed ID: 32129900
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous hidradenoma: a study of 21 neoplasms revealing neither correlation between the cellular composition and CRTC1-MAML2 fusions nor presence of CRTC3-MAML2 fusions.
Kyrpychova L; Kacerovska D; Vanecek T; Grossmann P; Michal M; Kerl K; Kazakov DV
Ann Diagn Pathol; 2016 Aug; 23():8-13. PubMed ID: 27402217
[TBL] [Abstract][Full Text] [Related]
20. Multiple eccrine poromas in the setting of total body irradiation and immunosuppression.
Mahlberg MJ; McGinnis KS; Draft KS; Fakharzadeh SS
J Am Acad Dermatol; 2006 Aug; 55(2 Suppl):S46-9. PubMed ID: 16843124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
